The use of metformin in adolescents with polycystic ovary syndrome: For and against

Journal of Pediatric and Adolescent Gynecology

Volumn 15, Issue 2, 2002, Pages 109-114

  Jamieson, Mary Anne ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ORAL CONTRACEPTIVE AGENT;

DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENDOCRINE DISEASE; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MENSTRUATION DISORDER; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; TREATMENT OUTCOME; CORONARY ARTERY DISEASE; ENDOMETRIUM CANCER; HIRSUTISM; MALE TYPE ALOPECIA; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; REVIEW; WEIGHT REDUCTION;

EID: 0036273828     PISSN: 10833188     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-3188(02)00137-7     Document Type: Article

References (1)

1. Metformin therapy in polycyptic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy